The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.
Be diagnosed as DLBCL
Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment
Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail
Cohort 3: relapse or refractory to previous treatment
Participant who currently participates in or with plan to participate in any interventional clinical trial
Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.